Overview
Precision HEOR provides specialized consulting in health economics and outcomes research, helping biotech and pharmaceutical clients demonstrate the value of innovations. It builds economic models, conducts evidence synthesis, and analyzes real-world data to translate clinical and economic information into clear value messages for regulators, payers, and providers. The firm differentiates itself through deep HEOR expertise and tailored guidance for market access and commercialization, using robust methodologies. Its goal is to help clients secure favorable market access and optimize product development and commercialization by clearly communicating the economic and clinical value of their innovations.
Work here?Claim your company
Simplify's take
What believers are saying
- LinkedIn lists 51-200 employees, signaling meaningful scale for a specialist consultancy.
- July 2026 and November 2026 Scientist.com sponsorships show active go-to-market momentum.
- 2026 leadership visibility under Mark Clein and Ross Maclean supports cross-sell and account access.
What critics are saying
- Precision Medicine Group can reallocate work, reducing PRECISIONheor to a brand wrapper.
- HEOR consulting commoditizes quickly; pricing pressure hits labor-heavy projects and margins.
- Without proprietary data or software, larger CROs can displace PRECISIONheor on enterprise accounts.
What makes PRECISIONheor unique
- Embedded inside Precision Medicine Group, pairing HEOR with access and medical communications.
- 95-plus researchers span modeling, epidemiology, biostatistics, and real-world evidence analysis.
- Sponsor-led webinars and Scientist.com visibility keep PRECISIONheor close to biotech buyers.
Help us improve and share your feedback! Did you find this helpful?